Goldman Sachs Group Analysts Give Novartis (VTX:NOVN) a CHF 105 Price Target

Goldman Sachs Group set a CHF 105 target price on Novartis (VTX:NOVN) in a research report released on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently issued reports on NOVN. UBS Group set a CHF 90 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Tuesday, September 10th. Deutsche Bank set a CHF 90 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Monday, September 16th. Barclays set a CHF 80 price objective on shares of Novartis and gave the stock a sell rating in a research report on Thursday, September 5th. Credit Suisse Group set a CHF 88 price objective on shares of Novartis and gave the stock a neutral rating in a research report on Friday, July 19th. Finally, Jefferies Financial Group set a CHF 100 price objective on shares of Novartis and gave the stock a buy rating in a research report on Friday, August 30th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of CHF 90.85.

Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.



Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: Lock-Up Period Expiration

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.